Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 115

1.

Sunitinib targets PDGF-receptor and Flt3 and reduces survival and migration of human meningioma cells.

Andrae N, Kirches E, Hartig R, Haase D, Keilhoff G, Kalinski T, Mawrin C.

Eur J Cancer. 2012 Aug;48(12):1831-41. doi: 10.1016/j.ejca.2012.01.032. Epub 2012 Mar 3.

PMID:
22391574
[PubMed - indexed for MEDLINE]
2.

Sunitinib induces PTEN expression and inhibits PDGFR signaling and migration of medulloblastoma cells.

Abouantoun TJ, Castellino RC, MacDonald TJ.

J Neurooncol. 2011 Jan;101(2):215-26. doi: 10.1007/s11060-010-0259-9. Epub 2010 Jun 4.

PMID:
20524040
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer.

Brooks C, Sheu T, Bridges K, Mason K, Kuban D, Mathew P, Meyn R.

Radiat Oncol. 2012 Sep 11;7:154. doi: 10.1186/1748-717X-7-154.

PMID:
22967802
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors.

Kumar R, Crouthamel MC, Rominger DH, Gontarek RR, Tummino PJ, Levin RA, King AG.

Br J Cancer. 2009 Nov 17;101(10):1717-23. doi: 10.1038/sj.bjc.6605366. Epub 2009 Oct 20.

PMID:
19844230
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

PDGFR signaling blockade in marrow stroma impairs lung cancer bone metastasis.

Catena R, Luis-Ravelo D, Antón I, Zandueta C, Salazar-Colocho P, Larzábal L, Calvo A, Lecanda F.

Cancer Res. 2011 Jan 1;71(1):164-74. doi: 10.1158/0008-5472.CAN-10-1708. Epub 2010 Nov 19.

PMID:
21097719
[PubMed - indexed for MEDLINE]
Free Article
6.

Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.

Huang D, Ding Y, Li Y, Luo WM, Zhang ZF, Snider J, Vandenbeldt K, Qian CN, Teh BT.

Cancer Res. 2010 Feb 1;70(3):1053-62. doi: 10.1158/0008-5472.CAN-09-3722. Epub 2010 Jan 26.

PMID:
20103629
[PubMed - indexed for MEDLINE]
Free Article
7.

SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.

Patyna S, Laird AD, Mendel DB, O'farrell AM, Liang C, Guan H, Vojkovsky T, Vasile S, Wang X, Chen J, Grazzini M, Yang CY, Haznedar JO, Sukbuntherng J, Zhong WZ, Cherrington JM, Hu-Lowe D.

Mol Cancer Ther. 2006 Jul;5(7):1774-82.

PMID:
16891463
[PubMed - indexed for MEDLINE]
Free Article
8.

Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.

Castillo-Avila W, Piulats JM, Garcia Del Muro X, Vidal A, Condom E, Casanovas O, Mora J, Germà JR, Capellà G, Villanueva A, Viñals F.

Clin Cancer Res. 2009 May 15;15(10):3384-95. doi: 10.1158/1078-0432.CCR-08-2170. Epub 2009 May 5.

PMID:
19417025
[PubMed - indexed for MEDLINE]
Free Article
9.

Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma.

Hui EP, Lui VW, Wong CS, Ma BB, Lau CP, Cheung CS, Ho K, Cheng SH, Ng MH, Chan AT.

Invest New Drugs. 2011 Dec;29(6):1123-31. doi: 10.1007/s10637-010-9451-1. Epub 2010 May 15.

PMID:
20467883
[PubMed - indexed for MEDLINE]
10.

Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.

Bai L, Yang JC, Ok JH, Mack PC, Kung HJ, Evans CP.

Int J Cancer. 2012 Jun 1;130(11):2693-702. doi: 10.1002/ijc.26303. Epub 2011 Sep 14.

PMID:
21792888
[PubMed - indexed for MEDLINE]
11.

Vascular endothelial growth factor signals through platelet-derived growth factor receptor β in meningiomas in vitro.

Pfister C, Pfrommer H, Tatagiba MS, Roser F.

Br J Cancer. 2012 Nov 6;107(10):1702-13. doi: 10.1038/bjc.2012.459. Epub 2012 Oct 9.

PMID:
23047550
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities.

Christensen JG.

Ann Oncol. 2007 Sep;18 Suppl 10:x3-10. Review.

PMID:
17761721
[PubMed - indexed for MEDLINE]
Free Article
13.

Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors.

McDermott U, Ames RY, Iafrate AJ, Maheswaran S, Stubbs H, Greninger P, McCutcheon K, Milano R, Tam A, Lee DY, Lucien L, Brannigan BW, Ulkus LE, Ma XJ, Erlander MG, Haber DA, Sharma SV, Settleman J.

Cancer Res. 2009 May 1;69(9):3937-46. doi: 10.1158/0008-5472.CAN-08-4327. Epub 2009 Apr 14.

PMID:
19366796
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies.

Papaetis GS, Syrigos KN.

BioDrugs. 2009;23(6):377-89. doi: 10.2165/11318860-000000000-00000. Review.

PMID:
19894779
[PubMed - indexed for MEDLINE]
15.

Study of the cellular mechanism of Sunitinib mediated inactivation of activated hepatic stellate cells and its implications in angiogenesis.

Majumder S, Piguet AC, Dufour JF, Chatterjee S.

Eur J Pharmacol. 2013 Apr 5;705(1-3):86-95. doi: 10.1016/j.ejphar.2013.02.026. Epub 2013 Feb 27.

PMID:
23454556
[PubMed - indexed for MEDLINE]
16.

Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of gastrointestinal stromal tumor.

George S.

Curr Oncol Rep. 2007 Jul;9(4):323-7. Review.

PMID:
17588358
[PubMed - indexed for MEDLINE]
17.

Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor.

Wang D, Tang F, Wang S, Jiang Z, Zhang L.

Cancer Chemother Pharmacol. 2012 Jan;69(1):173-83. doi: 10.1007/s00280-011-1681-1. Epub 2011 Jun 3.

PMID:
21638122
[PubMed - indexed for MEDLINE]
18.

Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia.

Hu S, Niu H, Minkin P, Orwick S, Shimada A, Inaba H, Dahl GV, Rubnitz J, Baker SD.

Mol Cancer Ther. 2008 May;7(5):1110-20. doi: 10.1158/1535-7163.MCT-07-2218.

PMID:
18483300
[PubMed - indexed for MEDLINE]
Free Article
19.

Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase.

Mahboobi S, Uecker A, Sellmer A, Cénac C, Höcher H, Pongratz H, Eichhorn E, Hufsky H, Trümpler A, Sicker M, Heidel F, Fischer T, Stocking C, Elz S, Böhmer FD, Dove S.

J Med Chem. 2006 Jun 1;49(11):3101-15.

PMID:
16722630
[PubMed - indexed for MEDLINE]
20.

SU5416 and EGCG work synergistically and inhibit angiogenic and survival factors and induce cell cycle arrest to promote apoptosis in human malignant neuroblastoma SH-SY5Y and SK-N-BE2 cells.

Mohan N, Karmakar S, Banik NL, Ray SK.

Neurochem Res. 2011 Aug;36(8):1383-96. doi: 10.1007/s11064-011-0463-9. Epub 2011 Apr 7.

PMID:
21472456
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk